Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

The Potent New Anti-Tumor Immunotherapies (D1)


Organizer(s) Nicholas P. Restifo
March 28—April 2, 2007
Fairmont Banff Springs • Banff, Alberta Canada
Abstract Deadline: Nov 28, 2006
Late Abstract Deadline: Jan 12, 2007
Scholarship Deadline: Nov 28, 2006
Early Registration Deadline: Jan 29, 2007

Sponsored by sanofi-aventis

Summary of Meeting:
For the first time, significant numbers of patients with some solid cancer histologies can be successfully treated using immunological means. Progress in our understanding of immune activation, homeostasis and regulation has reached a “tipping point” that has enabled the development of multiple anti-tumor immune-based strategies. Adoptive cell transfer (ACT) of anti-tumor T cells after the depletion host immune cells causes objective regression in about 50% of the patients. Work on therapeutic cancer vaccines is intensive and will actively be discussed at the meeting. The challenge now is to control and direct the potent new weapons in at the immunotherapist’s disposal. This meeting will bring the key scientists who are securing the basic foundations of the new immunology and the translational immunotherapists who are pioneering strategies that objectively work in the clinic.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


WEDNESDAY, MARCH 28

15:00—19:30
Registration

Van Horne Foyer
18:30—19:30
Refreshments

Van Horne Foyer
19:30—21:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
David Baltimore, California Institute of Technology, USA
Engineering Immunity to Cancer and other Diseases

Luigi M. Naldini, San Raffaele Telethon Institute, Italy
Novel Approaches to Regulate Transgene Expression and Enhance the Efficacy and Safety of Gene Therapy


THURSDAY, MARCH 29

07:00—08:00
Breakfast

Alberta, New Brunswick, Cascade, Conservatory
08:00—09:00
Morning Lecture
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Steven A. Rosenberg, NCI, National Institutes of Health, USA
Current Immunotherapies Based on Lymphodepletion and Adoptive Cell Transfer

09:00—09:20
Coffee Break

Van Horne Foyer
09:20—11:15
Adoptive Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Malcolm K. Brenner, Baylor College of Medicine, USA
Adoptive Immunotherapy of EBV-Associated Malignancies with EBV-Specific Cytotoxic T-Cell Lines

Philip D. Greenberg, University of Washington, USA
Engineering T Cells for Adoptive Transfer

* James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Blockade in Cancer Therapy

11:15—13:00
Poster Setup

Alberta, New Brunswick, Cascade, Conservatory
13:00—22:00
Poster Viewing

Alberta, New Brunswick, Cascade, Conservatory
14:00—15:30
Editor's Forum

Van Horne AB
* Linda J. Miller, AACR, USA
Scientific Journals, Plagiarism and Fraud

Juan Carlos Lopez, Haystack Science, USA
Challenges in Producing (and Publishing) Translational Research

Heather L. Van Epps, Journal of Experimental Medicine, USA
1896: Experimental Medicine Then and Now

15:30—16:30
Special Lecture
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Regulatory T Cell Function is Mediated by the Novel Inhibitory Cytokine Interleukin-34

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Programing of T Cells and Differentiation
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Carl H. June, University of Pennsylvania, USA
Adoptive Immunotherapy: New Ways to Skin the Cat?

Federica Sallusto, Università della Svizzera Italiana & ETH Zurich, Switzerland
Understanding the Generation and Function of Memory T Cell Subsets

* Stephen P. Schoenberger, La Jolla Institute for Allergy and Immunology, USA
Programmed Tolerance of CD8+ T Cells by B Cell APC

19:00—20:00
Social Hour with Lite Bites

Alberta, New Brunswick, Cascade, Conservatory
19:30—22:00
Poster Session 1

Alberta, New Brunswick, Cascade, Conservatory

FRIDAY, MARCH 30

07:00—08:00
Breakfast

Alberta, New Brunswick, Cascade, Conservatory
08:00—09:00
Morning Lecture
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Nicholas P. Restifo, NCI, National Institutes of Health, USA
The Future of Adoptive Immunotherapy

09:00—09:20
Coffee Break

Van Horne Foyer
09:20—11:30
Lymphodepletion
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
* Charles D. Surh, La Jolla Institute for Allergy and Immunology, USA
Potentials of T Cell Homeostatic Cytokines

Yang Liu, University of Michigan, Ann Arbor, USA
Short Talk: CD24 Controls T Cell Homeostasis and Cancer Resistance

Hyam I. Levitsky, Juno Therapeutics, USA
In vivo Depletion of Immune Regulatory Factors

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Establishing T Cell Memory by Adoptive Transfer of T Cell Clones

11:30—13:00
Poster Setup

Alberta, New Brunswick, Cascade, Conservatory
13:00—22:00
Poster Viewing

Alberta, New Brunswick, Cascade, Conservatory
14:00—14:30
Special Lecture

Van Horne A/B
Robert H. Wiltrout, NCI, National Institutes of Health, USA
Immunotherapy of Cancer by IL12-based Cytokine Combinations

14:30—16:30
Workshop 2A

Van Horne A/B
Phillip K. Darcy, Peter MacCallum Cancer Centre, Australia
Investigation of the Role of Gene-Modified CD4+ T Cell Subsets for Cancer Immunotherapy

Wolfgang Uckert, Humboldt-University, Germany
Enhanced Functional Expression of T Cell Receptors by Genetic Modification and Vector Optimization

Jacob Schachter, Sheba Medical Center, Israel
Adoptive Immunotherapy

Antoni Ribas, University of California, Los Angeles, USA
PET Imaging of Adoptive Transfer Immunotherapy

* Michael H. Kershaw, Peter MacCallum Cancer Center, Australia
Targeting a Carbohydrate Antigen using T Cells Modified with a Humanized Chimeric Receptor Gene

14:30—16:30
Workshop 2B

Van Horne C
Mary Jo Turk, Dartmouth Hitchcock Medical Center, USA
The Induction of T Cell Memory in the Absence of Tregs after Surgical Excision

Shimon Slavin, International Center for Cell Therapy & Cancer Immunotherapy, Israel
Cell-Mediated Immunotherapy of Hematological Malignancies and Metastatic Solid Tumors

Weiping Zou, University of Michigan, USA
Tregs, Th17 and their regulation in the tumor microenvironment

Sjoerd H. van der Burg, LUMC, Netherlands
Human Tumor-Specific Regulatory T-Cells in Therapeutic Vaccination Strategies

Jill E. Slansky, University of Colorado Health Sciences Center, USA
Relating TCR-Peptide-MHC Affinity to Immunogenicity

* Karin U. Jooss, Gritstone Oncology, USA
GM-CSF Transduced Cancer Cell Immunotherapies in Combination with Anti-CTLA4: Of Mice and Men

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Triggering Self Recognition
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Pamela S. Ohashi, Princess Margaret Cancer Centre, Canada
Cytokines are critical regulators of anti-tumor immunity

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Short Talk: The Hybrid Nature of Altered Self: Structural Basis for MHC Class II-Restricted TCR Recognition of a Mutant Tumor Antigen

Elizabeth M. Jaffee, Johns Hopkins University, USA
Tipping the Immune System Balance in Favor of Effective Anti-Cancer Therapy

* Linda A. Sherman, The Scripps Research Institute, USA
Immune Tolerance to Persistent Antigens and Dealing with the Consequences for Tumor Immunotherapy

19:00—20:00
Social Hour with Lite Bites

Alberta, New Brunswick, Cascade, Conservatory
19:30—22:00
Poster Session 2

Alberta, New Brunswick, Cascade, Conservatory

SATURDAY, MARCH 31

07:00—08:00
Breakfast

Alberta, New Brunswick, Cascade, Conservatory
08:00—11:00
Dendritic Cells
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
* A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA
Understanding the Interplay of the Human Immune System with Cancer in Humanized Mice

Lieping Chen, Yale University, USA
Co-Stimulatory and Co-Inhibitory Receptor-Ligand Pairs

Vincenzo Cerundolo, University of Oxford, UK
Harnessing NKT cells in cancer vaccination strategies

Andrew L. Mellor, Georgia Regents University, USA
Immunoregulatory Plasmacytoid Dendritic Cells Expressing Indoleamine 2,3 Dioxygenase (IDO)

Patrick Hwu, University of Texas MD Anderson Cancer Center, USA
Short Talk: Use of Activated Plasmacytoid Dendritic Cells to Induce Antitumor Immunity

09:20—09:40
Coffee Break

Van Horne Foyer
11:00—13:00
Poster Setup

Alberta, New Brunswick, Cascade, Conservatory
13:00—22:00
Poster Viewing

Alberta, New Brunswick, Cascade, Conservatory
14:00—14:30
Special Lecture

Van Horne AB
Vincenzo Bronte, University of Verona, Italy
Myeloid Suppressor Cells in Cancer

14:30—16:30
Workshop 3A

Van Horne A/B
Franck Housseau, Johns Hopkins School of Medicine, USA
Interferon-Producing Killer Dendritic Cells

Naoto Hirano, Princess Margaret Cancer Centre, Canada
IL-21 Mediated Expansion of Antigen-Speciific CD8+ T Cells

Diana F. Hausman, Zymeworks, USA
Clinical Studies of IL-21 in the Immunotherapy of Cancer

Reno Debets, Erasmus MC Cancer Institute, Netherlands
IL-21 Promotes Naieve T Cell Phenotype and Antigen-Specific Functions in TCR-Transduced T Cells

* Gosse J. Adema, University Medical Center, NCMLS Nijmegen, Netherlands
The Impact of Toll-Like Receptors on Regulatory T Cells

14:30—16:30
Workshop 3B

Van Horne C
Peter P. Lee, Stanford University School of Medicine, USA
Downregulation of Interferon-Signaling Pathways in Lymphocytes from Metastatic Melanoma Patients

Paul R. Walker, Geneva University Hospital, Switzerland
Functional Differentiation of CD8 T Cells during the Effector Phase of Brain Tumor Immunity

Nathalie Rufer, Swiss Institute for Experimental Cancer Research, Switzerland
In vivo Clonal Distribution and Longevity of Functional Human Tumor Antigen Specific T Cells

* George Coukos, University Hospital of Lausanne - CHUV, Switzerland
Regulation of T Cell Trafficking by Tumor Endothelium: Implications for Immunotherapy

Mikael J. Pittet, Massachusetts General Hospital, USA
Noninvasive in vivo Assessment of CTL Delivery at the Tumor Site

Michelle Krogsgaard, New York University School of Medicine, USA
Imaging Sensitivity of T-Cell Recognition of Melanoma Antigens

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Visualizing T Cell Target Cell Interactions in Real-Time
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
* Mark M. Davis, Stanford University, USA
T Cell Recognition

Andrey S. Shaw, Washington University School of Medicine, USA
Antigen Recognition and Immunological Synapse Formation

Alex Y.C. Huang, Case Western Reserve University School of Medicine, USA
Short Talk: Chemokine Guidance of Cellular Cooperation During Primary Adaptive Immune Response

Rajat Varma, Xencor Inc., USA
Short Talk: A Dynamic View of the Immunological Synapse

19:00—20:00
Social Hour with Lite Bites

Alberta, New Brunswick, Cascade, Conservatory
19:30—22:00
Poster Session 3

Alberta, New Brunswick, Cascade, Conservatory

SUNDAY, APRIL 1

07:00—08:00
Breakfast

Alberta, New Brunswick, Cascade, Conservatory
08:00—09:00
Concluding Keynote Address
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Rafi Ahmed, Emory University School of Medicine, USA
Inducing Functional Immune Responses or CD8 T Cell Memory

09:00—09:20
Coffee Break

Van Horne Foyer
09:20—11:30
Genetically Engineering Cells for Adoptive Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Prospects and Limitations of T Cell Receptor Gene Therapy

Ken-ichi Hanada, National Cancer Institute, National Institutes of Health, USA
Short Talk: Genetic Engineering of T Cells for the Recognition of Renal Cell Tumors

Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada
From Stem Cells to T-Cells in vitro, a Toolkit for Cellular Immunotherapy

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Cancer Immunotherapy via Manipulation of T Cell Activation and Tumor Microenvironment

14:00—16:30
Workshop 4A

Van Horne A/B
* Lili Yang, California Institute of Technology, USA
Gene Modification of Hematopoietic Stem Cells

Linda Liu, Maxcyte Corp, USA
Genetically Engineering Cells at Industrial Scale for Immunotherapy

Hans J. Stauss, Royal Free College, UK
Exploiting T Cell Receptor Genes for Cancer Immunotherapy

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Novel Genetic Strategies to Enhance T Cell Function

Cyrille J. Cohen, Bar-Ilan University, Israel
Genetically Engineering Human T Cell Receptor Structure

14:00—16:30
Workshop 4B

Van Horne C
* Thomas Gajewski, University of Chicago, USA
T Cell Anergy as a Mechanism of Immune Escape

Charles Drake, Johns Hopkins University, USA
STAT3 is required for Il-17 and Il-23 in the Tumor Microenvironment

Pawel Kalinski, University of Pittsburgh, USA
Reciprocal Impact of Effector and Memory CD8+ T Cells on the Effectiveness of Cancer Vaccines

Mark Selby, Bristol Myers-Squibb, USA
Combination of CTLA-4 and PD-1 Blockade Induces Potent Anti-Tumor Responses

Martin L. Ashdown, ImmunAid P/L, Australia
Breaking a Deadly Cycle: Succesful Timed Treg Lymphodepletion in Cancer - Is it Already Happening Accidentally in the Oncology Clinic with Standard Drugs?

Wilfred A. Jefferies, University of British Columbia, Canada
Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas

Annette Paschen, German Cancer Research Center, Germany
Generation of the Melan-A/MART-1 CTL Epitope - How Cellular Proteases Reduce the Specific T Cell Stimulatory Capacity of Melanoma

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Future Work for the Clinic
Meeting has ended...abstracts no longer viewable online.

Van Horne AB
Rienk Offringa, Genentech Inc., USA
The Potential and Pitfalls of Targeting Cancer through Self-Antigens

Pedro Romero, Ludwig Institute for Cancer Research, Switzerland
New Clinical Vaccine Trials

* Bruce R. Blazar, University of Minnesota, USA
Umbilical Cord Blood Transplant (UCBT) as a Platform for Inducing Anti-Leukemia Immune Responses

19:00—20:00
Social Hour with Lite Bites

Alberta, New Brunswick, Cascade, Conservatory
20:00—23:00
Entertainment

Alberta, New Brunswick, Casade, Conservatory

MONDAY, APRIL 2

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA124284-01




We gratefully acknowledge additional support for this conference from:

Sanofi US

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676